NCT01268761View on ClinicalTrials.gov

GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Ovarian Hyperstimulation SyndromeEffects of GonadotropinOocyte Maturation
Interventions
DRUG

GnRH antagonist (Cetrorelix)

•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval

DRUG

Placebo (saline solution)

• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval

Trial Locations (1)

46015

IVI Valencia, Valencia

All Listed Sponsors
lead

Instituto Valenciano de Infertilidad, IVI VALENCIA

OTHER

NCT01268761 - GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome | Biotech Hunter | Biotech Hunter